KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Gross Margin (2022 - 2025)

Historic Gross Margin for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Q3 2025 value amounting to 183.81%.

  • Recursion Pharmaceuticals' Gross Margin fell 2375000.0% to 183.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 59.01%, marking a year-over-year decrease of 940800.0%. This contributed to the annual value of 23.12% for FY2024, which is 186600.0% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Gross Margin stood at 183.81%, which was down 2375000.0% from 4.88% recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Gross Margin peaked at 100.0% during Q1 2021, and registered a low of 183.81% during Q3 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' median Gross Margin value was 9.27% (recorded in 2023), while the average stood at 1.0%.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Gross Margin skyrocketed by 1002300bps in 2023, and later plummeted by -2375000bps in 2025.
  • Recursion Pharmaceuticals' Gross Margin (Quarter) stood at 100.0% in 2021, then crashed by -79bps to 20.74% in 2022, then tumbled by -55bps to 9.27% in 2023, then tumbled by -2056bps to 181.43% in 2024, then dropped by -1bps to 183.81% in 2025.
  • Its Gross Margin stands at 183.81% for Q3 2025, versus 4.88% for Q2 2025 and 48.04% for Q1 2025.